Soleno Therapeutics found using ticker (SLNO) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 9 and 8 with the average target price sitting at 8.67. Given that the stocks previous close was at 1.95 this would imply there is a potential upside of 344.6%. The day 50 moving average is 1.94 and the 200 moving average now moves to 1.95. The company has a market capitalisation of $154m. You can visit the company’s website by visiting: http://soleno.life
Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017. Soleno Therapeutics was incorporated in 1999 and is headquartered in Redwood City, California.